← Back to patent-cliff list
Quinolisin
Tier C — Watch / tradeQuinolisin
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ADRA1A
Indications (approved)：Benign prostatic hyperplasia
Regional status
US
-
EU
-
China
Phase II
2024-06-19
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Quinolisin?
Approved indications include: Benign prostatic hyperplasia.
When does the Quinolisin patent expire?
No public expiry year is available for Quinolisin yet; this page updates once verified.
How do I get a quote for Quinolisin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01